About 900 reports

  • GASTROINTESTINAL THERAPEUTICS MARKET, GLOBAL, CLINICAL TRIAL DURATION BY
  • shows that, when gastrointestinal clinical trials are segmented by molecular target,

Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape Summary Gastrointestinal disorders are common, and a number of them have a large patient population. Across the seven major markets (the US, the UK, France,...

  • Clinical Trial
  • World
  • Market Size
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited

ipage=##& xml=##& quest=##& rid=##& section=##& sequence=-##& pdf=##& dn=## [Accessed February ##, 2017].

  • Clinical Trial
  • Forecast
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

GLP-## agonists have been associated with a common side effect of gastrointestinal disturbances such as nausea and vomiting, which can reduce patient compliance (Prasad-Reddy and Isaacs, 2015).

  • Clinical Trial
  • World
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Eli Lilly & Co.

Additionally, as CF is a multi-system disease pancreatic, gastrointestinal and reproductive problems will remain even if the lung transplant is successful.

  • Clinical Trial
  • World
  • Market Size
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.

Phase ## and Phase ##, then phase ## WHICH ONE IS THE FASTEST GROWING?

  • Clinical Trial
  • World
  • Forecast
  • Market Size
  • Supply
  • Clinical Trials by E7 Countries: Proportion of Functional (Non Ulcer) Dyspepsia to Gastrointestinal Clinical Trials
  • Clinical Trials by G7 Countries: Proportion of Functional (Non Ulcer) Dyspepsia to Gastrointestinal Clinical Trials

Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H1, 2015" provides data on the Functional (Non Ulcer) Dyspepsia clinical trial scenario. This report provides elemental information and data...

  • Clinical Trial
  • World
  • Actavis plc
  • Astellas Pharma Inc.
  • Zeria Pharmaceutical Co., Ltd.

Minor AEs such as stomatitis, headaches, fatigue and gastrointestinal problems such as nausea and vomiting may occur when using Metolate.

  • Clinical Trial
  • World
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.

Gastrointestinal Cancer Research; ##(##): ##-## Mayo Clinic (2014).

  • Clinical Trial
  • World
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson

DURING CHILDHOOD, ASTHMA IS MORE COMMON IN MALES, WITH A MALE-TO-FEMALE RATIO OF ##:## UP TO PUBERTY, WHEN IT CHANGES TO ##:##.

  • Clinical Trial
  • Respiratory Monitoring
  • World
  • Market Size
  • Astellas Pharma Inc.

As such, non-selective COX inhibitors typically produce COX-## inhibitory gastrointestinal (GI) side effects, including gastric ulceration, bleeding and perforation.

  • Clinical Trial
  • World
  • Market Size
  • Allergan plc
  • Amgen Inc.

Biologics are susceptible to metabolism in the gastrointestinal tract and lack permeability, which collectively leads to poor bioavailability.

  • Clinical Trial
  • World
  • AbbVie Inc.
  • Galapagos NV
  • Pfizer Inc.

When gastrointestinal AEs were reported their intensity was much lower than with oxycodone.

  • Clinical Trial
  • World
  • Amgen Inc.
  • Daiichi Sankyo Company
  • Eli Lilly & Co.
  • Ph ase I
  • Pharmaceutical Industry, Clinical Trial Duration in Phase I by Therapy Area, 2006-

Health Affairs; ##(##): ##-## Vernon J, et al. (2010).

  • Clinical Trial
  • Pharmaceutical
  • Therapy
  • United States
  • Market Size

Heparin is given intravenously due to poor gastrointestinal tract absorbability.

  • Clinical Trial
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

The ACURATE family of valve products is one of two valve systems in the Boston Scientific structural heart portfolio.

  • Clinical Trial
  • Prosthesis
  • United States
  • Edwards Lifesciences Corporation
  • Valtech Cardio, Ltd.

Gastrointestinal Cancer Research; ##(##): ##-## Hurwitz H, et al. (2004).

  • Cancer
  • Clinical Trial
  • World
  • Market Size
  • Merck & Co., Inc.

This method avoids the gastrointestinal tract and leads to more rapid effects, compared to orally administered levodopa.

  • Clinical Trial
  • World
  • Biogen Idec Inc.
  • Novartis AG
  • Roche Group

GLP-## IS AN INCRETIN HORMONE THAT IS RELEASED FROM CELLS IN THE GASTROINTESTINAL TRACT INTO THE CIRCULATION IN RESPONSE TO INGESTED NUTRIENTS FROM FOOD.

  • Clinical Trial
  • Southeast Asia
  • Market Size
  • Novo Nordisk Group
  • Sanofi S.A.

Dietary factors have a substantial influence on the risk of cancers of the gastrointestinal tract.

  • Clinical Trial
  • World
  • Market Size
  • Juno Therapeutics Inc.
  • Merck & Co., Inc.

Indian Journal of Ophthalmology; ##(##): ## Pfizer.

  • Clinical Trial
  • World
  • Forecast
  • Market Size
  • Clearside Biomedical, Inc.

One-year treatment of obesity: a randomized, double-blind, placebocontrolled, multicenter study of orlistat, a gastrointestinal lipase inhibitor.

  • Clinical Trial
  • World
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novo Nordisk Group

The Pharma Innovation; ##(##): ##-## Bresnick GH (1983).

  • Clinical Trial
  • World
  • Adverum Biotechnologies, Inc.
  • Alcon, Inc.
  • Allergan plc

Report Title Published Date ##.

  • Clinical Trial
  • North America
  • United States
  • World
  • Horizon Discovery

IMRT HAS HELPED TO DECREASE THE OCCURRENCE OF GASTROINTESTINAL (GI) TOXICITIES USUALLY ASSOCIATED WITH EBRT.

  • Clinical Trial
  • Hormone
  • Prostate Cancer
  • Therapy
  • PROVENGE group
  • LINZESS: CURRENT STATUS OF DEVELOPMENT
  • 8.3.7. CLINICAL STUDIES

DIGESTIVE AND GASTROINTESTINAL DISORDERS DIGESTIVE AND GASTROINTESTINAL DISORDERS ARE ONE OF THERAPEUTIC AREAS THAT ARE TARGETED BY SEVERAL ORAL PEPTIDE / PROTEIN THERAPEUTICS THAT ARE EITHER MARKETED OR UNDER DEVELOPMENT.

  • Clinical Trial
  • North America
  • United States
  • Ironwood Pharmaceuticals, Inc.
  • Novo Nordisk Group

Overall, there was one serious adverse event of moderate gastrointestinal infection that was determined by the investigator not to be drugrelated.

  • Clinical Trial
  • World
  • Forecast
  • Market Size
  • Pharming Group NV

Surgery; ##(##): ##-##.

  • Clinical Trial
  • Market Size
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

Neurologic side effects such as headaches and visual abnormalities, as well as gastrointestinal disorders have also been reported.

  • Clinical Trial
  • World
  • Market Size
  • AbbVie Inc.
  • Janssen Biotech, Inc.

The latter compound, tegafur, is orally available but has been associated with a high level of gastrointestinal toxicity due to early metabolism of the drug in the gastrointestinal tract.

  • Clinical Trial
  • World
  • Market Size
  • AstraZeneca PLC
  • Merck & Co., Inc.

Patients may develop gastrointestinal perforations, in which case treatment is stopped immediately.

  • Clinical Trial
  • World
  • AstraZeneca PLC
  • Novartis AG
  • Roche Group